Decentralized real-world study of digital therapeutic indicated for chronic insomnia enrolls first participant

Written by Ilana Landau, Editor

Pear Therapeutics (MA, USA) has announced that the first participant has been enrolled in its decentralized, real-world clinical study of an FDA-authorized prescription digital therapeutic indicated for adults with chronic insomnia. The 9-week long trial – termed the ‘DREAM’ study – plans to enroll approximately 350 adults with chronic insomnia to evaluate the effectiveness of Somryst™ as a treatment strategy for the condition. Somryst is a prescription-only digital therapeutic that provides a form of cognitive behavioral therapy for insomnia and can be used on smartphones and other mobile devices. The fully site-less, virtual clinical trial infrastructure of the DREAM study...

To view the full article, please register now for access

It's completely free